| Drug Type Antibody drug conjugate (ADC) | 
| Synonyms- | 
| Target | 
| Action inhibitors | 
| Mechanism CDH3 inhibitors(Cadherin 3 inhibitors) | 
| Therapeutic Areas | 
| Inactive Indication- | 
| Originator Organization | 
| Active Organization | 
| Inactive Organization- | 
| License Organization- | 
| Drug Highest PhasePreclinical | 
| First Approval Date- | 
| Regulation- | 

| Indication | Highest Phase | Country/Location | Organization | Date | 
|---|---|---|---|---|
| Metastatic Prostate Carcinoma | Preclinical | United States  | 29 Apr 2025 | |
| Metastatic Prostate Carcinoma | Preclinical | Japan  | 29 Apr 2025 | |
| Metastatic Triple-Negative Breast Carcinoma | Preclinical | United States  | 29 Apr 2025 | |
| Metastatic Triple-Negative Breast Carcinoma | Preclinical | Japan  | 29 Apr 2025 | 






